Given the clinical efficacy observed in targeting ERBB2 amplification in the closely related p53-mutated endometrial serous carcinoma [23], we focused on the focal FGFR1 copy number gain/amplification as a novel and potentially targetable molecular alteration in uterine carcinosarcoma. The gene discussed is TP53; the disease is uterine carcinosarcoma.